incretin receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Naturally occurring rhodium is composed of only one isotope, 103Rh. With a nuclear spin of -1/2, 103Rh is well-suited for nuclear magnetic resonance spectroscopic studies. With a particularly low nuclear dipole moment, 103Rh exhibits very low receptivity. The most stable radioisotopes are 101Rh with a half-life of 4.07 years, 102Rh with a half-life of 207 days, and 99Rh with a half-life of 16.1 days. Thirty-eight other radioisotopes have been characterized ranging from 90Rh to 128Rh; these have half-lives that are less than an hour except 100Rh (20.8 hours) and 105Rh (35.34 hours). Numerous meta states are also known, of which the most stable are 102mRh (3.742 years) and 101mRh (4.343 days). In isotopes lighter than 103Rh (the stable isotope), the primary decay mode is electron capture and the primary decay product is ruthenium. In isotopes heavier than 103Rh, the primary decay mode is beta emission and the primary product is palladium.
Skin and skin structure Infections This medication can be used to treat skin and skin structure infections caused from beta-lactamase-producing strains of S. aureus, Enterobacter spp., E. coli, Klebsiella spp. (including K. pneumoniae), P. mirabilis, B. fragilis, and Acinetobacter calcoaceticus. Examples of skin conditions treated with ampicillin-sulbactam are moderate to severe diabetic foot infections and type 1 Necrotizing fasciitis, commonly referred to as "flesh-eating bacteria".
In contrast, siRNAs typically base-pair perfectly and induce mRNA cleavage only in a single, specific target. In Drosophila and C. elegans, miRNA and siRNA are processed by distinct Argonaute proteins and Dicer enzymes.
Protein phosphorylation is highly conserved in pathways central to cell survival, such as cell cycle progression relying on cyclin-dependent kinases (CDKs), but individual phosphorylation sites are often flexible. Targets of CDK phosphorylation often have phosphosites in disordered segments, which are found in non-identical locations even in close species. Conversely, targets of CDK phosphorylation in structurally defined regions are more highly conserved. While CDK activity is critical for cell growth and survival in all eukaryotes, only very few phosphosites show strong conservation of their precise positions. Positioning is likely to be highly important for phosphates that allosterically regulate protein structure, but much more flexible for phosphates that interact with phosphopeptide-binding domains to recruit regulatory proteins.
Sources: en.wikipedia.org
If she can only cook as well as Honeywell can compute. Her souffles are supreme, her meal planning a challenge? She's what the Honeywell people had in mind when they devised our Kitchen Computer. She'll learn to program it with a cross-reference to her favorite recipes by N-M's own Helen Corbitt. Then by simply pushing a few buttons obtain a complete menu organized around the entree. And if she pales at reckoning her lunch tabs, she can program it to balance the family checkbook. 84A 10,600.00 complete with two week programming course. 84B Fed with Corbitt data: the original Helen Corbitt cookbook with over 1,000 recipes 5.00 (.75) 84C Her Potluck, 375 of our famed Zodiac restaurant's best kept secret recipes 3.95 (.75) Corbitt Epicure 84D Her Tabard Apron, one-size, ours alone by Clairdon House, multi-pastel provincial cotton 26.00 (.90) Trophy Room
== Research contributions == Balalaie's research focuses on several areas of organic chemistry, including environmentally friendly synthetic methods and pharmaceutical applications. His research group has worked on the development of multicomponent reactions (MCRs), particularly for the synthesis of heterocyclic compounds. His work in this area has included the use of zeolite catalysts for the preparation of tetrasubstituted imidazoles and other heterocycles. His research has also involved developing synthetic routes for several active pharmaceutical ingredients (APIs). Compounds published by his group include: Zoledronic acid, Gabapentin, Deferasirox and Pantoprazole. In peptide synthesis, Balalaie's work has included the synthesis of therapeutic peptides such as triptorelin, leuprolide, octreotide, and oxytocin. His group has also designed cyclopeptides containing heterocyclic structures (imidazole, thiazole, oxazole) intended to serve as potential anticancer agents. His book "Peptide Chemistry in Persian" was recognized as a winner of the Iran Book of the Year Award in 1399 (2020).
=== Dietary === The relation between dietary fat and atherosclerosis is controversial. The USDA, in its food pyramid, promotes a diet of about 64% carbohydrates from total calories. The American Heart Association, the American Diabetes Association, and the National Cholesterol Education Program make similar recommendations. In contrast, Prof Walter Willett (Harvard School of Public Health, PI of the second Nurses' Health Study) recommends much higher levels of fat, especially of monounsaturated and polyunsaturated fat. These dietary recommendations reach a consensus, though, against consumption of trans fats. The role of eating oxidized fats (rancid fats) in humans is not clear. Rabbits fed rancid fats develop atherosclerosis faster. Rats fed DHA-containing oils experienced marked disruptions to their antioxidant systems, and accumulated significant amounts of phospholipid hydroperoxide in their blood, livers and kidneys. Rancid fats and oils taste very unpleasant in even small amounts, so people avoid eating them. Measuring or estimating the actual human consumption of these substances is challenging. Highly unsaturated omega-3 rich oils such as fish oil, when being sold in pill form, can hide the taste of oxidized or rancid fat that might be present. In the US, the health food industry's dietary supplements are self-regulated and outside of FDA regulations. To protect unsaturated fats from oxidation, it is best to keep them cool and in oxygen-free environments.
After the prey has been digested, the cone snail will regurgitate any indigestible material, such as spines and scales, along with the harpoon. There is always a radular tooth in the radular sac. A tooth may also be used in self-defense when the snail feels threatened. The harpoon attack of the species Conus catus has been found to be one of the fastest complete movements recorded in animals, with a maximum speed of 90 km/h (56 mph), an acceleration of 400,000 m/s2, and a deceleration of 700,000 m/s2. The speed of other animals such as the peacock mantis shrimp and the trap-jaw ant was measured at the free end of a fixed appendage, while the speed of the harpoon was measured from its base and traveling inside the proboscis. The reason for this speed relies in hydrostatic pressure by the fluid inside the proboscis which propels the harpoon inside until it is almost completely out. A sphincter acts as a valve to keep fluid in the proximal half and in the distal half a constriction of ephitelial tissue together with a thicker harpoon base helps to build up hydrostatic pressure when the sphincter opens. The deceleration may help release the venom from the harpoon.
She initially attempts to use her powers on Jasmine, but learns of Jasmine's ESP and tries to make the latter her pet instead. Despite being mortally wounded by Blitz, Succubus dies transferring her lifeforce to him. During the events of the crossover film Tokusou Sentai Dekaranger vs. Abaranger, Saunaginnan revives Succubus, who is subsequently deleted by Deka Pink and Yellow and Abare Yellow. Succubus Hells is portrayed by Mayu Gamō (蒲生 麻由, Gamō Mayu). Reversian Blitz Hells (リバーシア星人ブリッツ・ヘルズ, Ribāshia Seijin Burittsu Heruzu): The oldest, cruelest, and most powerful of the Hells Siblings who possesses energy-based powers, wields a sword and a machine gun-like blaster, is willing to sacrifice his siblings, and earned a reputation as the "Outer Space Grim Reaper" (宇宙の死神, Uchū no Shinigami). After being defeated by the Dekarangers, he attempts to escape in God Pounder, only to be deleted by Riding Dekaranger Robo. Blitz Hells is voiced by Hiroshi Tsuchida (土田 大, Tsuchida Hiroshi). Tylerian Durden (タイラー星人ダーデン, Tairā Seijin Dāden): The owner and fight promoter of an illegal fight club, gambling operation, and illegal steroid ring from Planet Tyler. After recognizing the Dekarangers while they were infiltrating his fight club, he retaliates by piloting a demon-themed Kaijuki called Ultimate Evil (アルティメットイビル, Arutimetto Ibiru), only to be deleted by Super Dekaranger Robo. Durden is voiced by Masaharu Satō (佐藤 正治, Satō Masaharu).
Sources: en.wikipedia.org
On 14 September 2025, the Wall Street Journal reported the US and China have reached the "framework of a deal" for the US operations of TikTok to be sold to a consortium of investors in the US including close Trump ally Larry Ellison of Oracle. The deal was completed by 22 January 2026, with a consortium of investors—including Oracle, Silver Lake, MGX, and others including the personal investment entity for Michael Dell—owning more than 80% of the new venture. ByteDance retained 19.9% ownership. Under the deal, the app would remain the same, and the algorithm would be adjusted over time to favor American topics for those users.
The pharmacokinetics of progesterone are dependent on its route of administration. The medications is approved in the form of oil-filled capsules containing micronized progesterone for oral administration, termed oral micronized progesterone or OMP. It is also available in the form of vaginal or rectal suppositories or pessaries, topical creams and gels, oil solutions for intramuscular injection, and aqueous solutions for subcutaneous injection. Routes of administration that progesterone has been used by include oral, intranasal, transdermal/topical, vaginal, rectal, intramuscular, subcutaneous, and intravenous injection. Vaginal progesterone is available in the form of progesterone capsules, tablets or inserts, gels, suppositories or pessaries, and rings. The bioavailability of progesterone was commonly overestimated due to the immunoassay method of analysis failing to distinguish between progesterone itself and its metabolites. Newer methods have adjusted the oral bioavailbility estimate from 6.2 to 8.6% down to less than 2.4%.
The TV show Inside Amy Schumer premiered on Comedy Central on April 30, 2013. Inside Amy Schumer was picked up for a second season that began in 2014. A behind-the-scenes miniseries entitled Behind Amy Schumer premiered in 2012. The third season premiered on April 21, 2015, with a fourth season ordered the same day. In 2014, Schumer embarked on her Back Door Tour to promote the second season of her show. The show was closed by Bridget Everett, whom Schumer cites as her favorite live performer. She also appeared as a guest on an episode of comedian Jerry Seinfeld's Internet series Comedians in Cars Getting Coffee in 2014. She hosted the 2015 MTV Movie Awards, which took place on April 11. Schumer wrote and played her first leading film role in Trainwreck, co-starring Bill Hader, which was released on July 17, 2015. In August 2015, Jennifer Lawrence said she and Schumer planned to co-star in a film for which they and Schumer's sister Kim were co-writing a screenplay. However, Schumer later revealed the project was on the "back burner". Schumer performed as opening act for Madonna on three New York City dates of the singer's Rebel Heart Tour in September 2015. On October 17, 2015, Schumer's comedy special Amy Schumer: Live at the Apollo premiered on HBO. In 2016, it was nominated for three Primetime Emmy Awards for Outstanding Variety Special, Writing, and Directing. It also garnered her a nomination for the Grammy Award for Best Comedy Album. Schumer started her first world tour on August 26 in Dublin.
The lungs are not capable of expanding to breathe on their own, and will only do so when there is an increase in the volume of the thoracic cavity. This is achieved by the muscles of respiration, through the contraction of the diaphragm, and the intercostal muscles which pull the rib cage upwards as shown in the diagram. During breathing out the muscles relax, returning the lungs to their resting position. At this point the lungs contain the functional residual capacity (FRC) of air, which, in the adult human, has a volume of about 2.5–3.0 litres. During heavy breathing as in exertion, a large number of accessory muscles in the neck and abdomen are recruited, that during exhalation pull the ribcage down, decreasing the volume of the thoracic cavity. The FRC is now decreased, but since the lungs cannot be emptied completely there is still about a litre of residual air left. Lung function testing is carried out to evaluate lung volumes and capacities.
=== Sports injuries === According to several studies, creatine supplements decrease or at least do not increase the incidence of musculoskeletal injury, muscle cramping, and dehydration. In a study, creatine users had fewer incidences than non-users of muscle pulls/strains, muscle tightness, cramping, heat illness/dehydration, non-contact injuries, and total injuries/missed practices.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.